President & Chief Executive Officer
Michael O’Rand, PhD, is a retired professor in the Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, School of Medicine. Dr. O’Rand is a reproductive biologist and has more than 35 years of experience in studying mechanisms underlying human fertilization. Dr. O’Rand established the in vitro fertilization laboratory in UNC School of Medicine’s North Carolina Memorial Hospital and the first “test tube” baby in North Carolina. He has 5 issued or pending patents and more than 90 peer-reviewed publications. Dr. O’Rand has an AB from the University of California at Berkeley, an MS from Oregon State University, Corvallis, Oregon and a PhD in Biology from Temple University, Philadelphia, PA.
Senior Director of Operations
Katherine Hamil is a molecular biologist and biochemist with more than 30 peer-reviewd publications involving small secreted proteins and host defense in the male reproductive tract. She has 30 years of laboratory and project management experience and extensive repertoire of laboratory techniques. She trained and collaborated with MD and PhD students from many parts of the world. She has an BS from the University of Michigan at Ann Arbor and MS in Biochemistry from the University of North Carolina at Chapel Hill.
President and CEO of Eppin Pharma Inc
Michael O’Rand PhD, continues to use his grant writing skills to obtain funding for Eppin Pharma Inc from both NIH and private foundations. He also acts as the CSO in dealing with CRO's and other agencies.
Jeffrey A. Handler, PhD, DABT, MBA, is a Board certified toxicologist with broad experience in many areas of pharmaceutical and medical device research and development in multiple therapeutic areas, including antibacterials, therapeutic and aesthetic dermatology, stroke, Alzheimer’s disease, diabetes, urinary incontinence and rheumatoid arthritis, obtained over more than 27 years in the pharmaceutical business. He has extensive leadership and management skills within pharmaceutical R&D ranging from drug discovery through development and support of commercialized products and a track record of successful collaboration with colleagues in both scientific and commercial business areas. Dr. Handler has a PhD in Pharmacology from the University of North Carolina at Chapel Hill and an MBA from Villanova University.
Executive Chairman of the Eppin Pharma Inc Board of Directors
Zahed Subhan, PhD, MBA, JD, is a Professor of Entrepreneurship and Innovation at Drexel University, PA. Dr. Subhan has over 27 years of extensive experience in guiding pre-clinical studies, clinical development, commercialization, and fundraising. He has experience in gaining regulatory approvals from FDA and EMEA agencies as well as experience in executing major pharmaceutical product launches, including being responsible for a $100M NASDAQ IPO and subsequent $220M sale. As a CEO of multiple life science companies he was responsible for raising over $30M. As a member of Eppin Pharma’s BOD he will provide assistance and guidance in fundraising, business development. He has a PhD in Pharmacology from the University of Leeds, UK, an MBA from the University of Bradford, UK, and JD Law from the University of London, UK.
Distinguished Scientist and Director, Contraceptive Technology Innovation, FHI360, Durham, NC 27701 USA
Areas of expertise: Contraceptive technologies, HIV prevention research, Reproductive health, Hormonal contraception
Director, Research & Development, Global Health, Population & Nutrition, Contraceptive Technology Innovation, FHI360, Durham, NC 27701 USA
Areas of expertise: Reproductive health, Industry experience in women’s health (Wyeth), Contraceptive technology, reproductive (sperm and testis) biology
Professor of Medicine, Section Head, General Internal Medicine
University of Washington, Seattle WA
Areas of expertise: Board certified in internal medicine, Men’s reproductive health, Clinical evaluation of male contraceptives, Reproductive biology